Wells Fargo reaffirms its 'overweight' recommendation on Johnson & Johnson (J&J) despite a price target lowered from $178 to $170, based on a ratio of around 15 times its 2025 EPS assumption for the healthcare group.

Ahead of the December 5 investor day, the broker says it expects the focus to be on medium- and long-term prospects in pharmaceuticals and medical technologies, particularly growth in 2025 and beyond in pharmaceuticals.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.